$ABT News
Last published 1d ago
- 1d agoMSFTRTXSYKABT+1Christine Poole’s Top Picks for Nov. 10, 2026BNN BloombergTop Picks from Christine Poole, President & Co-Chief Investment Officer, Davis Rea
- 1w agoABTAbbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve diseasePR NewswireCROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement deviceAbbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve
- 2w agoABTAbbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPR NewswirePowered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part
- 2w agoABTAbbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancerPR NewswireBeta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1Building on its leadership in colorectal cancer screening with the Cologuard®
- 3w agoCMEABTLMTMHO+1Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold FirmPR NewswireVANCOUVER, BC, Oct. 21, 2026 /CNW/ -- Stock Preachers News Commentary - Three sessions into the week, growth and small caps are setting the pace. The Nasdaq Composite jumped 1.04% on the day and is up 2.14% for the week
- 3w agoABTAbbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS GuidancePR NewswireThird-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percentThird-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42Expands portfolio with key new product approvalsABBOTT
- 3w agoABTAbbott announces its intention to separate its global Nutrition business into an independent, publicly traded companyPR NewswireSeparation will unlock potential of both companies to pursue distinct growth and value-creation strategiesThe new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a
- 1mo agoSPCXMETATCOP+16Trump bought up to $25 million in Meta and millions in SpaceX debt in AugustCNBCTrump disclosed 517 August trades, including up to $5 million in debt from SpaceX, a major Pentagon contractor and NASA launch provider.
- 1mo agoABTAbbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoopPR NewswireMuscle support just got simpler. Abbott (NYSE: ABT) today announced the launch of Ensure Max Protein 3-in-1 Muscle Support, a protein powder that...
- 1mo agoABTAbbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart conditionPR NewswireAbbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF...
- 1mo agoABTAbbott hosts conference call for third-quarter earningsPR NewswireAbbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens. The announcement will be...
- 1mo agoABTAbbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolioPR NewswireAbbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening...
- 1mo agoABTAbbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic HealthPR NewswireAbbott (NYSE: ABT) and Berry Street today announced an exclusive partnership to help people take a more proactive approach to nutrition and long-term ...
- 1mo agoABTAbbott declares 411th consecutive quarterly dividendPR NewswireThe board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 411th consecutive...
- 1mo agoABTAbbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recallPR NewswireAbbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of...
- 2mo agoMCKBSXSYKABT+4Hackers claim millions of patient records stolen during data breach at healthcare giant McKessonTechCrunch
- 2mo agoABTAbbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formulaPR NewswireParents looking for an infant formula made with whole milk now have a new option. Abbott (NYSE: ABT) today announced the launch of Similac® 360 Total ...
- 2mo agoABTAbbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of strokePR NewswireAbbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a ...
- 2mo agoBSXABTMDTSYK+1Medical device maker Boston Scientific says a cyberattack is causing a ‘global disruption’ to its operationsTechCrunch
- 2mo agoABTAbbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetesPR NewswireAbbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day...
- 2mo agoABTAbbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infantsPR NewswireAbbott (NYSE: ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals...
- 2mo agoABTAbbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcarePR NewswireAbbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) announced a multi-year "food is medicine" effort – called the...
- 2mo agoABTFirst Bellwether Trial Today Against Reckitt Benckiser’s Mead Johnson in NEC Baby Formula MDL Led by Levin PapantonioBusiness WireReckitt Benckiser (LON: RKT) subsidiary, Mead Johnson is facing the first bellwether today as part of a multidistrict litigation (MDL) in the US District Court for the Northern District of Illinois over its infant
- 3mo agoABTAbbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisisPR Newswire"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company AbbottFor only the second time in its history, the
- 3mo agoABTAbbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AIPR NewswireMulti-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal healthPartnership includes a large-scale
- 3mo agoFRNMABTFDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.GlobeNewswire– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based
- 3mo agoABTAbbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS GuidancePR NewswireAbbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026. Second-quarter sales increased 13.0 percent on a...
- 4mo agoABTAbbott hosts conference call for second-quarter earningsPR NewswireAbbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens. The announcement will be...
- 4mo agoABTALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease TestingPR NewswireALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE:...
- 4mo agoABTNew Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parentsPR NewswireParenthood is widely anticipated as one of life's most fulfilling journeys, yet for today's new parents – especially Gen Z – that excitement is often ...
- 5mo agoABTAbbott declares 410th consecutive quarterly dividendPR NewswireThe board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 410th consecutive...
- 5mo agoABTNew Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosisPR NewswireAbbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected ...
- 5mo agoABTAbbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetesPR NewswireAbbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology...
- 5mo agoABTACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screeningPR NewswireAbbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that...
- 5mo agoABTAbbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026PR NewswireAbbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology...
- 6mo ago.SPX.IXICABTDHR+6Jim Cramer says today’s market is punishing stocks harder than 1999CNBCCNBC’s Jim Cramer said today’s market may resemble 1999 in some ways, but investors are punishing stocks even more aggressively.
- 6mo agoABTAbbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platformPR NewswireAbbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0...
- 6mo agoABTAbbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026PR NewswireAbbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation ...
- 6mo agoABTNew data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection TestPR NewswireAbbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued...
- 6mo agoABTAbbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesPR NewswireAbbott today (NYSE: ABT) announced financial results for the first quarter ended March 31, 2026. First-quarter sales increased 7.8 percent on a...
- 7mo agoABTNew survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their healthPR NewswireToday, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing ...
- 7mo agoABTAbbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platformPR NewswireAbbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology,...
- 7mo agoABTAbbott hosts conference call for first-quarter earningsPR NewswireAbbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be...
- 7mo agoABTJohn Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screeningPR NewswireAbbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is...
- 7mo agoABTAbbott completes acquisition of Exact SciencesPR NewswireAbbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer...
- 7mo agoABTAbbott acquisition of Exact Sciences set to close on March 23, 2026PR NewswireAbbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows...
- 8mo agoABTLandmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose managementPR NewswireAbbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using...
- 8mo agoABTAbbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'PR NewswireAbbott (NYSE: ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players aged 18–19 across the...
- 8mo agoABTTrial Set in NEC Multidistrict Litigation Against Reckitt Benckiser's Mead Johnson Led by Levin PapantonioBusiness WireReckitt Benckiser (LON: RKT) subsidiary Mead Johnson is facing a bellwether trial in the US Multidistrict Litigation (MDL) over infant formula product Enfamil linked to necrotizing enterocolitis (NEC) scheduled for 6
- 8mo agoABTEXASExact Sciences Stockholders Approve Acquisition by AbbottBusiness WireExact Sciences Corporation (NASDAQ:EXAS) ("Exact Sciences"), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences